Last reviewed · How we verify

NCT04371679: COVID-HO

Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients

Status unknown Last updated 15 March 2022
What this trial tests

trial testing No interventions planned in Covid-19 in 40 participants. Status unknown.

Timeline
1 April 2020
Primary endpoint
1 October 2022
1 December 2022

Quick facts

Lead sponsorHasselt University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment40
Start date1 April 2020
Primary completion1 October 2022
Estimated completion1 December 2022
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Hasselt University

Who can join

Eligibility, any sex, with Covid-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the study is to evaluate cardiac and pulmonary hemodynamic changes over time as predictor of disease progression and outcome in COVID-19 patients admitted to ICU. The primary endpoint is the occurrence of a major event predefined as either: death (all-cause mortality) or discharge from ICU (limit of 4 months). This is a uni-center prospective observational cohort study with an inclusion period of 2 months. The end of the study is foreseen in 6 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Evolution of cardiac function in COVID 19 patients in the intensive care unit: insights from machine learning
    Marti Castellote P, Loncaric F, Nogueira M, Sitges M, et al · · 2021

Verify or expand the search:

Other recruiting trials for Covid-19

Currently open trials in the same condition.

Other Hasselt University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04371679.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing